Date prepared: June 14, 2023<\/p>\n\n\n\n
Abbreviated name of the issuer: CELON PHARMA S.A.<\/p>\n\n\n\n
Subject: Admission and introduction of 21,500 ordinary C-series bearer shares of the Company to stock exchange trading<\/p>\n\n\n\n
Legal basis<\/p>\n\n\n\n
Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodic information<\/p>\n\n\n\n
Content of the report:<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby announces that on June 13, 2023 the Management Board of the Warsaw Stock Exchange (\u201cGPW\u201d) has adopted a resolution concerning the admission and introduction of the Company\u2019s ordinary C-series bearer shares to stock exchange trading on the GPW Main Market List.<\/p>\n\n\n\n
In its resolution, the Management Board of the GPW stated that pursuant to \u00a7 19.1 and \u00a7 19.2 of the WSE Rules, 21,500 ordinary C-series bearer shares of the Company, having the nominal value of PLN 0.10 each, designated with the \u201cPLCLNPH00080\u201d code by the Central Securities Depository of Poland, are admitted to stock exchange trading on the primary market.<\/p>\n\n\n\n
The GPW Management Board decided to introduce the above-mentioned shares of the Company to trading on the primary market as of June 19, 2023, subject to the assimilation of these shares with the shares in the exchange trade, designated with the \u201cPLCLNPH00015\u201d code, by the Central Securities Depository of Poland on June 19, 2023.<\/p>\n","protected":false},"excerpt":{"rendered":"